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Introduction and context {#s01}
========================

Lung cancer is the leading cause of cancer death in the world and progress in the treatment of the different diseases under this heading has been modest in the last 25 years. The two most important reasons for the lack of progress are the fact that the majority of patients with lung cancer present with advanced (metastatic) disease and that responses to systemic therapy most frequently are partial and of relatively short duration. About 85% of all patients with lung cancer have 'non-small cell' histology, and international guidelines indicate that four cycles of so-called platinum doublet chemotherapy are standard. These guidelines do not address histology or which platinum doublet.

Recent advances {#s02}
===============

A recent study has shown that pemetrexed/cisplatin was superior to gemcitabine/cisplatin in two subgroups of patients with non-small cell lung cancer (NSCLC): adenocarcinoma and large cell carcinoma. The gemcitabine/cisplatin combination performed better in patients with squamous cell carcinoma \[[@bib-001]\]. This important observation (that is, the increased sensitivity to specific chemotherapeutic agents in subgroups of patients with NSCLC) has been confirmed recently by others \[[@bib-002],[@bib-003]\]. The main target of pemetrexed is thymidylate synthase (TS). In NSCLC patients who underwent surgical resection, TS is expressed at a higher level in squamous cell carcinoma than in adenocarcinoma and this may well explain the better result of pemetrexed in adenocarcinoma.

These recent study results show that the oncological community now has the opportunity to leave the current practice of lumping different histologies together and to prescribe cytotoxic drugs on clinicopathological parameters. The art of selecting systemic therapy for NSCLC lies not only in knowing which drugs to use but also in the selection of subgroups of patients who are most likely to benefit from the treatment.

Another category of systemic agents for NSCLC is composed of oral tyrosine kinase inhibitors of the epidermal growth factor receptor (otherwise known as EGFR-TKIs). Two EGFR-TKIs, erlotinib and gefitinib, have been studied extensively in the last 6-7 years and were found to induce responses, improve symptoms, and in some instances to prolong survival in previously treated patients with NSCLC \[[@bib-004],[@bib-005]\]. During early clinical development of the two drugs, it had become apparent that patients with adenocarcinoma and patients with little or no exposure to cigarette smoke had better responses to these two agents; moreover, Southeast Asian patients seemed to respond better \[[@bib-006]\].

In 2004, independent groups of investigators suggested that increased sensitivity to EGFR inhibitors was related to specific mutations in the EGFR domain \[[@bib-007],[@bib-008]\]. Prospective studies studying the efficacy of erlotinib and gefitinib in patients with EGFR mutations seemed to confirm this hypothesis \[[@bib-009]\], and very recently a randomized study revealed that gefitinib performs better than chemotherapy in a preselected group of Asian patients with adenocarcinoma (light or never smokers) with an EGFR mutation, whereas patients without a mutation had a more favourable result on chemotherapy \[[@bib-010]\].

Implications for clinical practice {#s03}
==================================

Thus, there are multiple indications for the abandonment of the common practice of the last three decades of offering the same treatment to all patients with NSCLC. The studies cited above provide enough evidence to start using histology and mutation status as criteria for patient selection. The practical consequence of that will be a decrease in popularity of the fine-needle aspiration technique for diagnosis. Most likely, a cytological diagnosis will not be firm enough to serve as the basis for treatment advice in the near future. It is also worth mentioning that the determination of EGFR mutation status is quite laborious and needs an experienced hand. Therefore, it is generally felt that this selection criterion is not easily accessible to all oncology units. Solutions such as the introduction of specific diagnostic kits for EGFR mutations are currently being investigated.

The selection of subgroups of patients with NSCLC for therapy is becoming increasingly important. It is equally important to identify patients who are not likely to respond or live longer as a result of therapy. This is especially relevant for treatments related with significant toxicity or for which the cost-benefit ratio of the treatment is likely to be extremely high. An individualized treatment approach is becoming an important issue in NSCLC.
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